FIGURE 4.

Eltanexor treatment suppresses viral protein synthesis by targeting XPO1 for proteasome-mediated degradation. (A) Eltanexor treatment decreases XPO1 protein levels during the course of HCMV infection. HFFs were infected with HCMV at a MOI = 1 and treated with Eltanexor (0.4 μM) or DMSO. Cell lysates were collected at the indicated time points (hpi) and assayed by immunoblot for IE2, XPO1, and β-action. Protein band intensities were analyzed by Amersham Imager 600 analysis software. (B) Eltanexor treatment decreases the protein levels of XPO1 in a dose-independent manner. HFFs were infected with HCMV at MOI = 1 and treated with Eltanexor at the indicated concentrations or equal volumes of vehicle (DMSO). Cell lysate were collected at 72 hpi and immunoblotted and analyzed as in (A). (C) Eltanexor induced XPO1 degradation is inhibited by the proteasome inhibitor MG-132. HFFs were infected with HCMV at a MOI = 1 on ice for 1.5 h, and then grown in complete medium with Eltanexor (0.4 μM) and/or the proteasome inhibitor MG132 (5μM). Cell lysates were collected and assayed by immunoblot for IE1, XPO1, and β-actin.